Biofabrication holds the potential to generate constructs that more closely recapitulate the complexity and heterogeneity of tissues and organs than do currently available regenerative medicine therapies. Such constructs can be applied for tissue regeneration or as in vitro 3D models. Biofabrication is maturing and growing, and scientists with different backgrounds are joining this field, underscoring the need for unity regarding the use of terminology. We therefore believe that there is a compelling need to clarify the relationship between the different concepts, technologies, and descriptions of biofabrication that are often used interchangeably or inconsistently in the current literature. Our objective is to provide a guide to the terminology for different technologies in the field which may serve as a reference for the biofabrication community.
What Do We Mean by Biofabrication?
By combining the principles of engineering, biology, and material science, biofabrication holds great promise to change the toolbox for many biotechnological disciplines. Recently, in the context of tissue engineering and regenerative medicine applications, the definition of biofabrication as a research field was updated as 'the automated generation of biologically functional products with structural organization from living cells, bioactive molecules, biomaterials (see Glossary), cell aggregates such as micro-tissues, or hybrid cell-material constructs, through bioprinting or bioassembly and subsequent tissue maturation processes' [1] . This definition includes the fabrication of scaffolds with hierarchical structural properties or smart-surface properties within the realm of bioprinting. It was reasoned that the design of such features would be indispensable to obtain structurally functional biological substitutes. This work provided an overview of the historical evolution and broader meaning of the term, and also specified the research field with a focus on applications in tissue engineering and regenerative medicine, and proposed bioprinting and bioassembly as the two major approaches to biofabrication. Despite this definition and positioning of the field, as well as recent reviews that nicely provide a common framework to the additive manufacturing field at large [2] [3] [4] [5] , the terminology commonly used, especially in recent literature, is not clearly defined and lacks consensus. This absence of an agreed and accepted terminology can, and partially already does, lead to uncertainty or confusion in the description of new approaches and possible misunderstanding as to where a new report fits in relation to previous reports. This could impede the development of the field by making it difficult to correctly map progress in the science and technology of biofabrication.
We intend here to follow-up from our previous review updating the definition of biofabrication for tissue engineering and regenerative medicine applications [1] . We aim to set an overarching
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terminology framework by clarifying the technologies used within biofabrication strategies, as well as rationalizing appropriate terminologies, as an integral basis for communication in all the different application fields of biofabrication. We therefore feel that a brief review of classical and novel biofabrication approaches, with the aim to point out the differences among them and the limitations that must still be overcome, is timely. A Glossary of the main different terminologies clarified in this article is also provided in this article. We also point out potential future research directions where we believe biofabrication may have a major impact, with the objective to collaborate with industry to bring biofabrication strategies to the clinic in a more efficient and consensual manner, and to collectively overcome future regulatory and ethical challenges.
Technologies Used for Biofabrication
As previously indicated, biofabrication strategies employed for tissue engineering and regenerative medicine can be identified as either bioprinting or bioassembly. To further classify the various technologies used for these strategies in terms of efficiency of fabrication, we introduce the spatial resolution/time for manufacturing (RTM) ratio as a quantitative characterization of the process underlying a specific technology, considering the ability to produce scaffolds with fine details in a short time as a measure of merit. The RTM ratio is defined as:
Here, R is the best spatial resolution that can be achieved within the technology, and P is the delivery rate of the material being printed or assembled. R is expressed as the inverse of the minimum feature dimension, d: d is measured in m, thus R is measured in 1/m; P is expressed as the volume, V, of material (measured in m 3 ) delivered per unit of time, t (in minutes). As a consequence, the physical dimensions of the RTM ratio are square-length/time. In the biofabrication field, the order of magnitude of R and P are 1/mm and mm 3 /minute respectively: hence, the RTM ratio must be expressed in 10 À3 m 2 /minute for an easier comparison between different technologies. Note that, for each specific technology, R and P may vary, depending on the material delivered, as well as on the geometry of the scaffold and on its placement in the building chamber.
In the following sections, standard operating procedures are considered (such as commonly used materials, average printing parameters, single or multiple material deposition head) for building a 1 cm 3 cube of material (V = 10 À6 m 3 ), lying on one of its faces. Table 1 lists the average RTM ratios for the biofabrication technologies that will be considered in the present work. Figure 1 (Key Figure) gives a graphical representation of the distribution of the various biofabrication technologies in the parameter space with axes of minimum feature dimension d and delivery rate P: as explained above R and P may vary for each technology (represented by circles). In Figure 1 the contour lines of the RTM function are also plotted: technologies along the same contour line have the same RTM ratio. Generally speaking, the higher the value of the RTM ratio, the more efficient the process. Most technologies are placed along the diagonal of the 'd-P' parameter space, indicating that higher delivery rates result in lower resolution, and fabricating fine details is in contrast with fast manufacturing. We briefly here outline the most common technologies to illustrate and illuminate their differences, advantages, and limitations.
The most commonly used technologies in biofabrication with a major and active role of biomaterials in the printing process comprise (i) 3D printing; (ii) light-based technologies such as selective laser sintering (SLS), selective laser ablation, stereolithography (SLA), and two-photon polymerization (2PP); (iii) fused deposition modeling (FDM)/3D fiber deposition (3DF)/bioextrusion; (iv) wet-spun automated extrusion systems; (v) 3D plotting/bioplotting/robotic dispensing/extrusion bioprinting; (vi) ink-jet and valve-jet bioprinting; and (vii) electrospinning (Figure 2 ). Most of these technologies were originally developed as additive manufacturing technologies for rapid prototyping, but are included as biofabrication strategies when used for biomedical applications.
3D Printing
With 3D printing, a jet of binder is directed at a powder bed to define a pattern controlled by computer-aided design/computer-aided manufacturing (CAD/CAM) software. The solvent binds the powder, thus forming a slice of solid material; subsequently a new layer of powder is laid down and the process is repeated to build the scaffold layer-by-layer [6, 7] . The unbound powder acts as a support for the object during building, allowing the easy fabrication of reentrant and hollow objects. It can be difficult to remove excess unbound grains and remnants of used solvents/binder. In this respect, it is important to highlight that the term 3D printing should only refer to this specific additive manufacturing technology. This technology allows the 
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Long time for fabrication owing to cell spheroid production and construct maturation [71] [72] [73] [74] to fabricate a 10 À6 m 3 (1 cm   3 ) cube, lying on one of its faces. Fused deposition modeling/3D fiber deposition (3DF)/ bioextrusion: additive manufacturing technologies that can be used for bioprinting in which a thermoplastic material, in shape of filament or pellet, is hot-extruded and deposited to form a layer of solid material. Using a layer-by-layer approach a 3D scaffold or a 3D construct is built. Indirect additive manufacturing: a biofabrication approach that uses an additive manufactured mold in which a bioink is cast, injected, or compressed. Ink-jet and valve-jet bioprinting: printing systems able to bioprint constructs in a layer-by-layer manner by ejecting bioinks in the form of droplets via the nozzle head. Droplet ejection is controlled either by piezoor thermal actuators (ink-jet), or by solenoid microvalves (valve-jet). Laser-assisted bioprinting (LAB): also known as laser-induced forward transfer (LIFT), a bioprinting technique that uses laser pulses to deposit a bioink from a donor slide onto a substrate. Microfluidic technology: a technology based on geometrically constrained minute volume transport in micro-channels. This technology can also be used to fabricate strands of hydrogels that are suitable as building blocks for successive assembling processes. Micro-masonry concept: biofabrication approach in which microunits of cell-laden hydrogels are used as regenerative building blocks. Minimum feature dimension: the smallest detail that can be fabricated using a biofabrication technology. 3D plotting/bioplotting/robotic dispensing/extrusion bioprinting: bioprinting technologies that dispense continuous filaments of hydrogel materials that are extruded through nozzles using a piston, a screwing system, or pneumatic pressure as the driving force. Pressure-assisted microsyringe deposition (PAM)/wet-spun automated extrusion systems: additive manufacturing technologies that can be used for bioprinting based on the extrusion of polymers dissolved in volatile solvents. The quick evaporation of the solvent [7] Larger RTM [10 −3 m 2 /minute] represents a more efficient process [6] [12] [15] [18] [7] DLP [20] fabrication of structures with a lateral resolution controlled by a combination of the powder particle size and the volume that the solvent penetrates by capillary action. Current commercial systems have a feature resolution around 300 mm, which is suboptimal if precise control of cell positioning is required after scaffold fabrication. Its RTM ratio is about 0.1 Â 10 À3 m 2 /minute, and is thus at the medium level of manufacturing efficiency.
Light-Based Technologies SLS uses a laser where the beam of light is selectively directed to a powder bed, generating local heat and forming patterns of fused material; after its solidification, a new layer of powder is laid down and the process is repeated to build the scaffold layer-by-layer. A variety of thermoplastic polymers [8] , metals (in this case SLS is called 'selective laser melting'), ceramics, or mixtures of polymer-ceramic [9] and polymer-encapsulated ceramic [10] can be used, but the required high temperatures limit the utility of SLS for biofabrication processes. The source materials that are normally used require extra processing to obtain these in powder form with precise and narrow size granulometry. Selective laser ablation works in the opposite way by ablating a solid material using a very short duration laser pulse [11, 12] . If the ablation process is conducted in all of the three directions, or if laminated porous films are stacked and bonded on top of each other, a 3D structure can be created. These techniques have proved useful for the fabrication of improved tissue constructs upon seeding the scaffold with cells [13] [14] [15] . These technologies do not allow the direct incorporation of pharmaceuticals, biomacromolecules (proteins, growth factors), or cells into the scaffold. Thus, they could be considered as biofabrication technologies only when the fabricated scaffolds are designed following hierarchical or smart principles to influence cell activity and achieve functional biological constructs, as previously discussed [1] . In these methods the resolution of the printed pattern depends on the laser spot size, the thermal conductivity, the surface tension, the absorption of the raw materials, and grain size. Owing to heat conduction, resolution is inevitably larger than the spot size. The RTM ratio is $1 Â 10 À3 m 2 /minute for both technologies, which means that these techniques are fast even if the resolution is comparable to that of other methods.
A promising modification of SLS that can release active compounds (e.g., ribonuclease, an exceptionally stable enzyme) is surface selective laser sintering (SSLS) [16] , which uses an infrared laser to sinter powder substrates. In this case the radiation is not absorbed by the polymer particles but by carbon microparticles spread on the surface of the polymer particles. However, owing to several challenges, such as the use of carbon microparticles without a proven track record of biocompatibility, the processing of polymers into powder, and the lack of extensive studies with unstable biologically active compounds, this technology is not yet ready for the clinic.
SLA, in which light is used to solidify a photosensitive resin, has been typically used to produce a negative replica that is filled with ceramic or metallic slurries, and is subsequently removed by sintering at high temperatures [17] . Biocompatible and biodegradable photosensitive polymers that can be used in SLA to directly fabricate 3D scaffolds are also being developed and investigated. A few newly developed photosensitive resins are starting to appear in the biomaterials field for this purpose, and these have also opened the possibility to use a light allows shape retention of the 2D pattern deposited by the 3D micropositioner. With a layer-by-layer approach a 3D scaffold can be fabricated. 3D printing: an additive manufacturing technology that can be used for bioprinting in which a jet of binder is directed at a powderbed to define a pattern. The solvent binds to the powder, forming a slice of solid material; subsequently a new layer of powder is laid down, and the process is repeated to build the scaffold layer-by-layer. Resolution/time of manufacturing (RTM) ratio: a measure used to rank the performance of biofabrication technologies. The RTM ratio is defined as the ratio of the spatial resolution to the time required for biofabricating a bio-engineered structure; a larger RTM ratio represents a more efficient process. Selective laser ablation: an additive manufacturing technology that can be used for bioprinting in which a solid material is ablated using a very short time-duration laser pulse. If the ablation process is conducted in all the three directions, or if laminated porous films are stacked and bonded on top of each other, a 3D structure can be created. Selective laser sintering (SLS): an additive manufacturing technology that can be used for bioprinting in which a beam of laser light is selectively directed to a powder-bed, generating local heat and forming patterns of fused material; after its solidification, a new layer of powder is laid down and the process is repeated to build the scaffold layerby-layer. Stereolithography (SLA): an additive manufacturing technology that can be used for bioprinting in which light is used to cure a photosensitive resin. Through different irradiation approaches the various stereolithographic systems use a layer-by-layer approach: the energy delivered by the light is sufficient to solidify a particular thickness of the exposed resin and join this layer with the previous one. analogous to liquids, evidenced by the fact that irregular tissue fragments spontaneously round up into spheroids, and two fragments composed of different cell types mutually envelope each other. Such tissues can be quantified in terms of apparent tissue surface tension. Two-photon polymerization (2PP): a laser-based technique that uses a near-infrared ultrashort-pulsed laser to excite in a precise way and to confine space molecules (photoinitiators) to a two-photon state, triggering the polymerization of monomers in solution. This was the first technique that allowed the manufacturing of true 3D nano/ micro-structures without supports. projection system instead of a laser source (known as digital light processing, DLP TM ) [18, 19] .
Some of these also comprise hydrogel formulations, which would then allow the incorporation of cells into the biofabrication process. Despite enhanced resolution ($20-40 mm) with SLA, the biocompatibility of these photopolymers and of the photoinitiators used for their crosslinking remains to be fully validated. Incorporation of any biological material, including cells, depends on their sensitivity to the light source used [20] . In addition, this method is limited to a cell type that could be incorporated into a hydrogel. Using data in the literature, an RTM ratio of about 0.5 Â 10 À3 m 2 /minute can be estimated for SLA, which places this method among the more efficient techniques. In case of DLP, the RTM ratio can be increased to 2 Â 10 À3 m 2 / minute by parallelization of the light beam. An improvement of SLA with respect to spatial resolution is two-photon polymerization (2PP), where a spatially and temporally confined laser beam polymerizes a photosensitive resin [21, 22] . The resolution of this technology can reach the sub-micron scale. Although new photocurable biomaterials with satisfactory biocompatibility are being developed, and the speed of this fabrication process has improved, further progress in both materials development and fabrication rate is needed. The RTM ratio is 0.05 Â 10 À3 m 2 /minute, which means that 2PP has a very high resolution despite taking a long time to manufacture large structures.
Fused Deposition Modeling FDM has been extensively used to fabricate custom-made scaffolds and to modulate their mechanical properties for tissue engineering applications, with encouraging results [23] [24] [25] . In FDM, molten thermoplastic polymers are extruded into filaments. These filaments are deposited to form a layer, and a 3D scaffold is built layer-by-layer. The entire process is controlled by a CAD design. Several biocompatible thermoplastics have been developed and processed with this technique. However, the majority of published work to date has used polycaprolactone as the polymer of choice because of its relatively low melting temperature and its commercial availability in medical grades. Many other extrusion-based tools inspired by FDM have been developed to fabricate 3D scaffolds. These also comprise multi-dispensing systems, such as 3D fiber deposition (3DF) and bioextrusion, that allow the deposition of different materials and at the same time produce constructs with locally differing physicochemical properties [4, 23, 26] . The main difference between FDM on the one hand, and 3DF and bioextrusion on the other, is that in 3DF and bioextrusion the biomaterials are loaded into a cartridge as pellets or particles instead of being extruded in a filament form. This approach has the advantage of expanding the palette of biomaterials that can be used compared to FDM. An associated disadvantage of 3DF and bioextrusion is higher susceptibility to thermal degradation owing to the long residence times of the raw material at high temperatures. Although FDM, 3DF, and bioextrusion techniques have considerably improved the quality of tissue engineered constructs with respect to their functional performance [25, [27] [28] [29] , the high temperatures involved during the fabrication of molten polymers may limit the direct incorporation of biological factors by this technique. A solution could be envisaged if not only metallic [30] or ceramic pastes [31] are employed, but also polymeric pastes that can be processed at room temperature. Alternatively, surface modification techniques could be used to functionalize the fibers and allow grafting of bioactive agents at specific sites [32] . In addition, hydrogels that encapsulate biological components could be deposited together with thermoplastic materials, thereby circumventing the limitations [33, 34] imposed by the high temperatures. FDM, 3DF, and bioextrusion have the highest RTM (ii) 3D printing, (iii) fused deposition modeling, (iv) ink-jet printing, (v) 3D plotting, and (vi) solution and melt electrospinning. Adapted, with permission, from [118] [119] [120] .
ratio of most of all methods, around 1 Â 10 À3 m 2 /minute. Because the post-processing phase is practically nonexistent, there is a limited need for intervening layers or binders and solvents to remove excess material, as with most other techniques.
Pressure-assisted microsyringe deposition (PAM)/wet-spun automated extrusion systems have been developed to solve the disadvantages associated with high temperatures in FDM, at the same time achieving scaffolds with a higher fiber resolution ($80 mm for FDM vs 10 mm for PAM) [35, 36] . PAM is part of the PAM2 system in which several working modules can be mounted in parallel on a robotic micropositioner to allow simultaneous processing of synthetic and natural polymer solutions as well as living cell suspensions [36, 37] . The main drawback of wet-spun extrusion-based technologies is the low vertical dimension (when high resolution is sought), resulting in a medium RTM ratio of 0.5 Â 10 À3 m 2 /minute. This implies that thick constructs take more time to be fabricated than with other extrusion technologies. Recent progress by Lewis and colleagues might, however, solve such limitations by fabricating arrays of nozzles that can deposit multiple filaments at the same time [38] .
The major limitation of most scaffold fabrication processes reported in the literature is that each technique is applicable only in particular conditions (e.g., rheology, pressure, temperature, voltage) that restrict the choice of materials. Hydrogels composed of natural polymers (e.g., collagen, gelatin, hyaluronic acid), either in combination with additional biological factors or used alone, are intrinsically biocompatible and biodegradable, and possess biological cues [39] . However, these natural-polymer hydrogels are difficult to process with the techniques discussed so far. As an alternative, scaffolds made of natural biomaterials can be produced by indirect fabrication techniques (e.g., casting a biomaterial into a sacrificial mould formed by additive manufacturing processes). Indirect methods to produce additive manufactured scaffolds have emerged in several different approaches, with promising results [40] . The development of an alkali-soluble photopolymer allowed the use of indirect additive manufacturing with hydrogels [41] . In particular, gelatin and collagen scaffolds could be produced by applying indirect SLA manufactured moulds with high resolution and a minimum pore or strut size on the scale of several tens of micrometers [42, 43] . Indirect methods could be also combined with conventional techniques, such as salt leaching and phase inversion, to fabricate dual-pore scaffolds [44, 45] . Some drawbacks still exist with indirect approaches, including the poor resolution of the additive manufacturing techniques, the casting procedure, and the extraction methods. For these reasons the RTM ratio is $0.03 Â 10 À3 m 2 /minute.
Bioplotting and Ink-Jet Bioprinting
Whereas all of the above-mentioned methods have demonstrated different degrees of success in fabricating 3D scaffolds to accommodate cells that can develop into tissues or proto-tissue structures, most are incapable of simultaneously depositing biomaterials and cells. Therefore, cells need to be separately seeded into the scaffolds produced by these techniques. This limits the flexibility to mimic cell distributions in native tissues, particularly when strategies for the regeneration of multiple tissue interfaces or organs are to be developed. Three main sets of technologies have demonstrated the ability to incorporate cells during the process of additive manufacturing into a biomaterial carrier: 3D plotting (also known as bioplotting and extrusion bioprinting), ink-jet bioprinting, and valve-jet bioprinting. In bioplotting, the cells are typically encapsulated into a hydrogel carrier biomaterial and extruded by the application of pressure, similarly to wet-spun extrusion based technologies [46] [47] [48] . This technique allows the deposition of different cell types in different hydrogel formulations, but is still limited in terms of speed of production and fabrication of constructs with a complex shape, mostly because of the lack of optimal hydrogel carriers (also called bioinks). The technique also has some limitations if a stable structure is to be formed. For example, it may be necessary to use a plotting bath containing a fluid of matching density and viscosity to the extruded material to prevent sagging or deformation of the construct immediately after extrusion, or alternatively to use a hydrogel with sufficient viscosity to self-sustain its own weight after processing. An additional approach that has emerged is the extrusion of material into 3D space of another material, in contrast to building a structure from a surface [49] [50] [51] . This has been most commonly performed with hydrogels (e.g., continuous or colloidal suspensions) where the material displaces as another material is extruded into it, and has been used to print suspended objects or open-channel structures with the use of sacrificial materials.
In ink-jet bioprinting, cells encapsulated into hydrogel carriers are dispensed in droplet fashion. By ink-jet bioprinting it is possible to exquisitely control the number of cells per deposited droplet, thus resulting in a finer control over cell distribution in the fabricated constructs [52, 53] . The development of optimal hydrogels as bioinks for both bioplotting and ink-jet bioprinting remains a challenge, and the fluid requirements for both methods are very different in terms of fluid viscosity and surface tension [54] . The RTM ratio is $0.5 Â 10 À3 m 2 /minute for bioplotting as a consequence of rapid scaffold production but low resolution, and $0.1 Â 10 À3 m 2 /minute for ink-jet bioprinting due to high resolution but also high fabrication time per unit volume. In both technologies the presence of living cells in the bioink limits the RTM ratio: higher extrusion flow and smaller nozzles can induce damage due to shear stress on cell membranes [46] [47] [48] [49] [50] [51] [52] [53] .
Similar to the ink-jet technique, valve-jet bioprinting is a non-contact, droplet-based method where cells are printed with or without hydrogel carriers [55] . The actuation mechanism for the valve-jet is based on pneumatic pressure, and the ejection of droplets is controlled by solenoid microvalves instead of by piezo-or thermal actuators as in ink-jet printing [56] . Currently, the printing resolution (e.g., nanoliter droplet) and throughput (e.g., 1-1000 Hz) of valve-jet bioprinting lie between bioplotting and ink-jet bioprinting, as does the printable fluid viscosity range (up to 100 Pa.s). Because the technology is not limited by the nozzle size (as with ink-jet printing), shear stress can be minimized and therefore the technology is amenable to print delicate human pluripotent stem cells [57] . The RTM ratio is therefore $0.3 Â 10 À3 m 2 /minute for valve-jet bioprinting.
Electrospinning A further promising technique for scaffold fabrication is electrospinning. This technique produces fiber meshes with physical features mimicking those of the native extracellular matrix (ECM). The fiber meshes are created by passing a biomaterial solution through a high-voltage electric field near the deposition nozzle. At a defined voltage threshold, which is specific for a defined biomaterial solution, the surface tension of the biomaterial solution is overcome by the applied electric field, resulting in the formation of an electrohydrodynamic Taylor cone from which fibers are spun and collected on a grounded target plate [58, 59] . Despite being a relatively old technology, originally developed for textile fiber production, this technique is now widely used by the tissue engineering and regenerative medicine community because of the wide range of materials available for the technique and the methods of fiber collection that allow an expansive spectrum of structures and shapes to be fabricated [60, 61] . An important recent development in the field of electrospinning is the possibility to control the deposition of fibers at the scale of a single fiber. This has been achieved by the so-called near-field electrospinning technique for biomaterials in solution and by melt electrospinning writing for molten polymers [62] . Together they constitute a method of electrohydrodynamic writing in which predictable fiber paths are used to direct-write small-diameter fibers onto a translating collector. This new electrospinning modality can potentially be used to create scaffold structures that can better mimic the native ECM not only by the physical dimensions of the constituent fibers but also in terms of structural organization. Although cells have been shown to maintain their viability after electrospinning [63, 64] , reports describing the possibility of electrospinning cell-laden hydrogels are still limited [65, 66] . The RTM ratio of this technique is currently around 0.1 Â 10 À3 m 2 /minute.
In addition to the techniques listed so far, several alternative biofabrication strategies that use biomaterials only to provide structural integrity have been developed (Figure 3 ). The first examples of these strategies were provided by the work of Forgacs and coworkers who dispensed cell spheroids and cylinders into a hydrogel bed using special-purpose extrusion bioprinters [67] [68] [69] . The hydrogel is used as a support, while a tissue-like structure forms by exploiting the biophysical principles of tissue liquidity that governs the fusion of adjacent cell aggregates. In this manner, branched vascular networks [67, 70] , nerve grafts [68, 71] , and other tissue modules [69] have been successfully fabricated. Additional applications of this technology resulted in commercial products in the form of architecturally and functionally correct human tissue constructs for drug toxicology essays [72] . The principal limitations of this approach are (i) the relatively slow fusion of the cell aggregates, which takes typically at least 24-48 h depending on the cells used, and may lead to a somewhat inhomogeneous construct; (ii) low spatial resolution owing to the use of micropipettes of relatively large diameter (300 or 500 mm) for the preparation and deposition of gels and cells; and (iii) the limited diffusion of nutrients when large constructs are fabricated. Owing to these limitations and to the low resolution of this method, its RTM ratio is less than 0.001 Â 10 À3 m 2 /minute.
(A) (D) (B) (C) (F) (E)
Temperature-responsive coaƟng A similar technology was developed by Nakayama and coworkers who used an ingenious skewering system [73, 74] wherein the cell spheroids are placed on fine metallic needles (i.e., skewers), geometrically positioned as to be consistent with the shape of the desired organ structure (e.g., tubular construct; Figure 4 ). The novelty in this technology is that the needles prevent the otherwise unavoidable shrinking of the construct upon fusion of the spheroids (at least in one direction). Others have used a tangram-based concept in which different cellular shapes were left to fuse with each other and self-assemble into a macroscopic tissue construct [75] [76] [77] . Achieving fully vascularized large constructs with these tissue liquidity-based strategies is still an open challenge. Owing to the long aggregation time of the cell aggregates, the RTM ratio is slow, less than 0.001 Â 10 À3 m 2 /minute.
Another approach developed originally by Chrisey and colleagues [78] , later further adopted by Guillemot and colleagues [79] , is based on laser-assisted bioprinting (LAB). This technique has also been known as laser-induced forward transfer (LIFT) and matrix-assisted pulsed laser evaporation (MAPLE). The deposition system is composed of three components: (i) a pulsed laser source, (ii) a target from which a biological material is printed, and (iii) a receiving substrate that collects the printed material. The target is made of a thin absorbing layer of metal (such as gold or titanium) coated onto a laser-transparent support (e.g., glass or a transparent polymer film). Organic materials (molecules or cells) are prepared in a liquid solution (e.g., culture media or a hydrogel precursor) and are deposited at the surface of the metal film. The laser pulse induces vaporization of the metal-absorbing layer, resulting in the production of a jet of liquid solution which is deposited onto the substrate [80] . The resolution of this system depends on parameters such as the thickness of the bioink layer coated onto the target, the surface tension and viscosity of the bioink, the wettability of the substrate, the laser fluence, and the air gap between the target and the substrate. LAB has a fairly low RTM ratio of around 0.04 Â 10 À3 m 2 / minute owing high resolution and long fabrication time, which implies that thick constructs need more time for manufacture compared to the other techniques described before, and sometimes the production time of large size structures is not compatible with cell processing times.
A different approach for the biofabrication of tissues and organs consists of bottom-up approaches ( Figure 3D -F) in which micro and nano modules are first engineered and used as building blocks to fabricate the targeted tissues. One of the most successful bottom-up approaches is represented by the cell-sheet engineering method developed by Okano and colleagues, where cells are cultured until they reach confluence on thermoresponsive culture plates, which can easily release the formed cell layers by switching the temperature from 37 C to room temperature [81] . Larger constructs comprising multiple layers placed together in a conventional layer-by-layer method have been fabricated and successfully brought to the clinic [82] . With a similar approach, L'Hereux and coworkers developed and brought to the clinic a layer-by-layer approach for fabricating vascular biological grafts from cell sheets [83] .
Another classic example is the micro-masonry concept pioneered by the laboratories of Khademhosseini and Demirci, among others, where micro-units of cell laden hydrogels are used as regenerative building blocks [84] [85] [86] . The modularity of this approach is limitless. Hydrogels of different compositions that embed different cells can be mixed. Recently, functionalization with DNA segments was also demonstrated, and this resulted in a more biological dynamic recognition of different building blocks during in vitro assembly [87] . Furthermore, such blocks can be also precisely positioned using microrobots [88] .
Despite the great flexibility promised by these methods, further studies will be necessary to effectively demonstrate the fabrication of clinically relevant large vascularized constructs to compensate for the known nutrient-diffusion limitations of most hydrogel systems. Similar approaches have been also developed by combining solid micro-and nanoparticles with cells, thus offering the advantage of engineering the shape and size of such objects, which can possibly offer further stimuli to direct cell differentiation, particularly when stem cells are used [89, 90] . Their use in combination with cells offers the possibility to impinge on cellular condensation, which results in tissue shrinking, thus offering the opportunity to maintain the dimensionality of large tissue constructs. For bottom-up approaches the RTM ratio is lower than 0.001 Â 10 À3 m 2 /minute; these low values are principally due to the long fabrication time for the production of cell sheets or microunits and the time required for the fusion of the different cell sheets or microunits.
Microfluidic technology has also boomed in the recent years to create tissue-on-chip platforms that can recapitulate key functions of targeted tissues and organs. These platforms are typically used in association with a biomaterial formulation, namely hydrogel networks, to culture cells in 3D and study mechanisms behind pathological events and possible treatments. Examples comprise studies on cancer metastasis, lung, liver, intestine, and vessels, among others [91] [92] [93] [94] [95] . Further development of these platforms will comprise the integration of sensors to monitor in real-time cell and tissue functionality, as well as other biomaterial formulations, to better replicate native ECM of the targeted tissues to be studied. A further advancement in these bio-assembly biofabrication strategies has been reported by Takeuchi and coworkers, where meter-long cellular fibers have been created through microfluidic technology and proved to be efficacious in the regeneration of several tissues in preclinical animal models [96] . Cellular fibers are created by encapsulating cell-containing ECM proteins in a pre-gel state in mechanically stable Ca alginate hydrogel carrier in a coaxial manner, and by dissolving the carrier hydrogel upon the gelation of the cell-containing ECM. These fibers have also been weaved, thus creating cellular fiber scaffolds [97] .
Implications for an Integral Terminology and Future Perspectives
In this review we have made a first attempt to define a metric that can compare the fabrication efficiency of the main current biofabrication technologies and that is usable with new methods as they are being developed. If used in the common range of biofabrication applications (i.e., minimum feature size d less than 500 mm), although dimensionally complex, the RTM ratio will objectively classify the continuous optimization and advances in current biofabrication technologies (Box 1). A practical example is the recent development of a new SLA technology by the group of DeSimone, called continuous liquid interface production (CLIP), which allows creating 3D objects 100-fold faster than conventional SLA [98] . Whether this technology could be translated to biomaterials or cell-laden hydrogels remains to be demonstrated, but an estimate of its RTM ratio is 5 Â 10 À3 m 2 /minute. In addition to constraints associated with the physical principles behind each technology and the chemistry of currently available biomaterials, the RTM ratio can be increased by parallelization of printing heads: light-based technologies better than others can exploit this route, and projection SLA (known as digital light processing, DLP TM ) is a clear and extreme example in this direction [19] . Another technological challenge is the fabrication of complex anatomically shaped constructs. Whereas current bioprinting technologies can already achieve non-intricate structures, the recent development of new colloidal inks and optimized bathing stages in which the bioprinting process takes place could offer new solutions to further increase the degree of complexity in mimicking native organs [50, 51] . In particular, the use of high buoyant density liquids [99] , sacrificial fugitive materials [100] , or granular gels [50, 101] as media into which bioinks are deposited is becoming a new exciting Box 
Factors Influencing the RTM Ratio
The RTM ratio and the 'd-P' parameter space can quantitatively and visually classify the various biofabrication technologies, respectively, and they can also indicate possible research directions to improve the efficiency of a specific technology. The RTM ratio is given by the printing rate and the minimum feature size achievable with a specific technology. This minimum feature size is determined by the physics beyond the fabrication process, strictly depending on the involved physical principles (e.g., photopolymerization, heat diffusion, and so on) and on the materials (polymers, ceramics, metals) and their physical state (solid, powder, liquid, gel, slurry). The spatial resolution can be improved by working on the development of new materials and processes rather than on technological optimization.
The printing rate can depend on the complexity of the printed shape, both in terms of geometry and multi-material composition (Table I) . Biofabrication technologies based on a 'vector scanning' strategy for tracing the trajectories that lead to construct fabrication result in longer printing time in case of complex geometries, compared to those based on 'raster scanning' or 'projection' strategies. Multimaterial composition can also increase the fabrication time if different materials cannot be processed at the same time. avenue to fabricate larger and more complex constructs. For a more in-depth review on supporting temporary sacrificial materials we refer elsewhere [102] .
With the development of new bioprinting processes, it is nowadays possible to manufacture tissues with different levels of complexity ( Figure 5A-C) . This is achieved by heterogeneous combinations of different cells and bioinks. The degree of complexity needed to mimic and eventually replace a tissue and ultimately an organ has started to be considered for constructs tested in vitro [103, 104] and in vivo [105] . With initial minor functional outcomes, further understanding of the level of mimicry and complexity necessary to achieve optimal functional tissue or organ replacement is expected as the field matures.
In the perspective of commercial-scale production, other standards of quality should be taken into consideration, such as: (i) accuracy, or how closely the output of a manufacturing output conforms to a tolerance within a specified dimensional range, and (ii) repeatability, which captures the ability of the equipment to produce consistent output, time after time. These parameters are necessary to reduce the extrinsic variability of the advanced tissue models owing to microenvironmental properties, limiting the intrinsic variability related to the cells themselves [40] . Quality control requires a consensus on metrology: limiting the discussion to geometrical consideration, a least-squares fit of a point cloud representing the scaffold (e.g., from a mCT scan) to its CAD model, can give a measure of the fabrication error [106, 107] . Interestingly, additive manufacturing processes allow for in-process inspection of the internal structure of a component. Furthermore, the accuracy over time (long-term stability) is directly related to the off-the-shelf availability and, in a more prosaic way, to shipping and storing methods [108] .
Finally, new hydrogels need to be developed that are able to maintain at the same time cell viability and activity, as well as the physical shape of the final printed construct [109] [110] [111] . The dynamic behavior of native ECM is an appealing feature that could be incorporated into new bioinks in future biofabrication strategies. In this respect, what is nowadays called 4D printing could allow such integration where the use of stimulus-responsive materials allows a spatiotemporal change in a 3D object [112, 113] . Whether we are really witnessing 4D printing, a process that should be defined as a programmed temporal shape change occurring during the 3D manufacturing itself, or not, is still to be clarified in the field. We advocate for cautious use of the term 4D printing because all reports so far published in literature show 3D objects that can change shape after the 3D manufacturing process. Nonetheless, these time-morphing 3D objects are certainly an exciting new development of conventional additive manufacturing, which would be thrilling to see to be translated into novel biofabrication strategies.
Concluding Remarks and Recommended Guidelines
As the biofabrication community expands and the applications of this technology grow, it is important to establish a set of definitions and terminology that will help to normalize discussion and reports of developments in the field (see Outstanding Questions). Some attempts have been already made in the case of 3D scaffolds; for example, the National Institute for Standards and Technology of the United States of America is adopting 3D scaffolds fabricated by additive manufacturing technologies as standards for 3D cell culture [114] . Further standards could be sought into the realm of advanced manufacturing, as recently pointed out by Hutmacher and coworkers, who coined the term 'additive biomanufacturing' when standard norms such as ASTM or ISO are applied to the biofabrication field [115] . In this context it is important to note that biomanufacturing means the use of living organisms to manufacture a product. In a recent review the term has been defined more precisely as 'a type of manufacturing that utilizes biological systems (e.g., living microorganisms, resting cells, plants, animals, tissues, enzymes, or in vitro synthetic (enzymatic) systems) to produce commercially important value-added biomolecules for use in the agricultural, food, energy, material, and pharmaceutical industries' [116] . Therefore, it is not clear what the combined term 'additive biomanufacturing' actually means. This should be defined before taking into account its use as part of an industrial norm. In the case that the biological systems considered by Zhang and colleagues are used as part of a fabrication approach, we wish to stress that, according to the most recent definition of biofabrication [1] , 'additive biomanufacturing' is a subfield of biofabrication.
We propose here a clarification and classification of the different biofabrication terminologies in current use. In this respect, we recommend that the term 3D printing no longer be used as a general term for all additive manufacturing technologies applied to biofabrication strategies because 3D printing represents only one such technology, as previously described. Instead, we recommend using the name of the specific technology used to create a biofabricated construct, as outlined in this article. When referring to more general biofabrication strategies in tissue engineering and regenerative medicine, we recommend using the two general terms bioprinting or bioassembly. As we previously defined [1] , bioprinting refers to the use of computer-aided transfer processes for patterning and assembling living and non-living materials with a prescribed 2D or 3D organization to produce bio-engineered structures; bioassembly refers to the fabrication of hierarchical constructs with a prescribed 2D or 3D organization through automated assembly of pre-formed cell-containing fabrication units generated via cell-driven self-organization or through preparation of hybrid cell-material building blocks. We advise members of the community to adopt this terminology approach in their new studies and that the media will report advances in the field with the correct language, instead of broadly using only the term 3D printing. 
